BBOT’s BBO-8520 Shows 65% ORR, 68% PFS and BBO-11818 Achieves 56% PDAC Reduction
BBOT’s BBO-8520 achieved a 65% objective response rate and 68% six-month progression-free survival in KRAS G12C NSCLC, with 100% partial responses in the first five G12C/STK11 or KEAP1 co-mutant patients at active doses. PanKRAS inhibitor BBO-11818 produced a 56% tumor reduction in PDAC, and cash funds operations into 2028.
1. Fourth Quarter and Full Year Financial Results
BBOT reported fourth quarter and full year 2025 financials, underscoring continued investment in R&D to advance its oncology pipeline and confirming a cash runway into 2028 to support planned clinical activities.
2. BBO-8520 Clinical Data
BBO-8520, an orally bioavailable dual-state KRAS inhibitor, demonstrated a 65% objective response rate and 68% six-month progression-free survival in KRAS G12C NSCLC monotherapy, and achieved 100% partial responses in the initial five G12C/STK11 or KEAP1 co-mutant patients when combined with pembrolizumab, with a differentiated liver safety profile.
3. PanKRAS Inhibitor and Upcoming Catalysts
The panKRAS inhibitor BBO-11818 delivered the first confirmed partial response in pancreatic ductal adenocarcinoma with a 56% tumor reduction and no dose-limiting toxicities. BBOT plans to initiate internal combination cohorts with BBO-10203 later in 2026 and expects multiple clinical readouts in the second half of 2026.